SCHEMBL7965835

SCHEMBL7965835

COc1cc(/C(C)=N/N(C)C(=O)C(OC)c2ccc(-n3cccn3)cc2)cc(OC)c1Br

nearest known ligand 0.59

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.43
MGLL Q99685 1/20 0.37
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7961624 0.84 PTPN1 (0.43) PTPN1
SCHEMBL7960680 0.83 RAB9A (0.45) PTPN1
SCHEMBL7962251 0.80 HIF1A (0.46) PTPN1
SCHEMBL7962255 0.79 PTPN1 (0.43) PTPN1
SCHEMBL2388610 0.75 MGLL (0.43) PTPN1MGLL
SCHEMBL19416747 0.75 RAB9A (0.48) PTPN1
SCHEMBL7950654 0.75 RAB9A (0.46) PTPN1
SCHEMBL2387077 0.75 PDE10A (0.41) PTPN1
SCHEMBL14693631 0.74 PTPN1 (0.40) PTPN1
SCHEMBL3216052 0.74 PTPN1 (0.40) PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118711-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2018-05-03 US disclosed
US-20180118711-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2018-05-03 US disclosed
US-9783521-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2017-10-10 US disclosed
US-9783521-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2017-10-10 US disclosed
EP-2310016-B1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORP (US) 2017-10-04 EP disclosed
US-20140038951-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2014-02-06 US disclosed
US-20140038951-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2014-02-06 US disclosed
US-8377930-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-02-19 US disclosed
US-8377930-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-02-19 US disclosed
WO-2010017236-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2010-02-11 WO disclosed
US-20100035872-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2010-02-11 US disclosed
US-20100035872-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118711-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A PTPN1 2176/4885MGLL 2081/4885ADORA2A 48/4885
US-20140038951-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A PTPN1 2176/4885MGLL 2081/4885ADORA2A 48/4885
US-20100035872-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A PTPN1 2176/4885MGLL 2081/4885ADORA2A 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.